Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats

Antimicrob Agents Chemother. 2005 Nov;49(11):4789-92. doi: 10.1128/AAC.49.11.4789-4792.2005.


Cpl-1, a pneumococcal phage lytic enzyme, was tested in rats with experimental endocarditis due to Streptococcus pneumoniae WB4. High-dose regimen Cpl-1 eliminated pneumococci from blood within 30 min and decreased bacterial titers in vegetations (>4 log10 CFU/g) within 2 h. Rapid bacterial lysis induced by Cpl-1 treatment increased cytokine secretion noticeably.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cytokines / biosynthesis
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / microbiology
  • Enzyme Therapy*
  • Enzymes
  • Pneumococcal Infections / drug therapy*
  • Pneumococcal Infections / microbiology
  • Rats


  • Cytokines
  • Enzymes
  • lysin, streptococcus bacteriophage